|
Focus Area
|
| 505(b)(2) |
| Asset Evaluation for Commercialization |
| Buffer System Optimization |
| Business Development Strategy |
| Clinical Development Strategy |
| Complex Generics |
| CPP Identification |
| CQA Linkage |
| Cryo-/Lyoprotectant Optimization |
| Development Gap Assessment |
| Diagnostic Stabilization Strategies |
| Freezing Optimization |
| Gastrointestinal Diagnostic Panels |
| HPLC Method Development |
| ICP-MS Method Development |
| Immunogenicity Method Development |
| IND-Enabling Programs |
| IND-Enabling Toxicology Support |
| Injectables |
| Large-Molecule Analytical Development |
| LC-MS/MS Method Development |
| Lyophilization |
| Lyophilization Cycle Development |
| Manufacturing Design Space Development |
| Miniaturized Diagnostic Systems |
| Multiplex Diagnostic Panel Development |
| Oral Liquids |
| Partnering Strategy |
| Peptide Stabilization Strategies |
| pH Stabilization |
| Phase I–III Planning |
| Pipeline Positioning |
| PK Bioanalytical Development |
| Platform Positioning |
| Point-of-Care Molecular Diagnostics |
| Preclinical Safety Evaluation |
| Primary Drying Optimization |
| Process Characterization |
| Product Lifecycle Development |
| Program Management |
| Protein Stabilization Strategies |
| Respiratory Diagnostic Panels |
| SaaS Platforms |
| Scale-Up Transfer |
| Secondary Drying Optimization |
| Technology Evaluation for Commercialization |
| TK Bioanalytical Development |
| Topicals & Semi-Solids |
| Toxicology Development Strategy |
| Urinary Diagnostic Panels |
| Vaccine Stabilization Strategies |
